A randomized, open-label, phase II study of lapatinib/capecitabine, lapatinib/vinorelbine, or lapatinib/gemcitabine in patients with ErbB2-amplified metastatic breast cancer progressing after taxane treatment: Results of an interim analysis (GLICO-0801/EGF111792)

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search DSpace


My Account